F-18 FDG PET/CT代谢肿瘤异质性分析预测临床疑似N2的非小细胞肺癌患者纵隔淋巴结转移
本研究纳入50例初诊非小细胞肺癌且术前CT和F-18 FDG PET/CT临床疑似N2的患者,用变异系数(COV)评估原发肿瘤代谢异质性。病理确诊纵隔淋巴结转移阳性组COV高于阴性组(p < 0.001),最佳截断值41.9,敏感度65.2%、特异度88.9%(AUC 0.84;p < 0.0001)。作者认为原发肿瘤COV可预测病理纵隔淋巴结转移,可能作为常规影像的补充。
要点
- 临床疑似N2的NSCLC患者中,原发灶代谢异质性COV在病理纵隔淋巴结转移阳性组更高(p < 0.001)。
- COV鉴别纵隔淋巴结转移的最佳截断值为41.9,敏感度65.2%、特异度88.9%(AUC 0.84)。
- 与其他代谢参数相比,COV对纵隔转移的预测能力更优(p = 0.001)。
核心结论
- 原发肿瘤代谢异质性(以COV定义)可预测临床疑似N2的NSCLC患者病理纵隔淋巴结转移,作者认为COV可能作为常规影像的补充,在活检前提供淋巴结信息。
研究设计与样本
- 纳入50例初诊NSCLC且术前CT和F-18 FDG PET/CT临床疑似N2的患者,以手术标本病理结果确认纵隔淋巴结转移,用变异系数(COV)评估原发肿瘤代谢异质性。
诊断标准与关键数值
- 病理确诊纵隔淋巴结转移阳性组COV高于阴性组(p < 0.001);鉴别转移与非转移的最佳截断值为41.9,敏感度65.2%、特异度88.9%(AUC 0.84;p < 0.0001);COV对纵隔转移的预测能力优于其他代谢参数(p = 0.001)。
临床应用与阅片要点
- 作者认为原发肿瘤COV可能作为常规影像的补充,在活检前提供淋巴结信息。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: Accurate prediction of pathological N2 metastasis is crucial for choosing the best therapeutic strategy for non-small cell lung cancer (NSCLC) patients. The aim of this study is to evaluate the usefulness of metabolic heterogeneity assessed by the positron emission tomography combined with computed tomography (PET/CT) using F-18 fluorodeoxyglucose (FDG) in primary NSCLC with clinically suspected N2 metastasis in predicting pathological mediastinal lymph node metastasis.
MATERIALS AND METHODS: Fifty patients with newly diagnosed NSCLC and clinically suspected N2 on preoperative CT and F-18 FDG PET/CT were included. Pathological results were confirmed by surgical specimens and the coefficient of variation (COV) was used to evaluate the metabolic heterogeneity of primary tumor mass by using F-18 FDG PET/CT.
RESULTS: Among the 50 patients with clinically suspected N2, 23 patients were pathologically confirmed as positive mediastinal lymph node metastasis and 27 patients were negative. Pathologically confirmed positive mediastinal lymph node metastasis group presented higher COV than the negative metastasis group (p < 0.001). An optimal cut-off value of 41.9 was proposed for discriminating metastasis from non-metastasis group. The sensitivity and specificity were 65.2% and 88.9%, respectively (AUC: 0.84; p < 0.0001). In addition, compared with other metabolic parameters, metabolic heterogeneity defined as COV showed the superior predictability of the mediastinal metastasis. (p = 0.001) CONCLUSION: Metabolic heterogeneity which was defined as COV of primary tumor could predict pathological mediastinal lymph node metastasis in NSCLC patients with clinically suspected N2. Therefore, COV of primary tumor may play a complementary role to conventional imaging in providing nodal information before taking biopsy.
引用
- Pahk K, Chung JH, Yi E, et al. Metabolic tumor heterogeneity analysis by F-18 FDG PET/CT predicts mediastinal lymph node metastasis in non-small cell lung cancer patients with clinically suspected N2. Eur J Radiol. 2018. PMID: 30150037. doi:10.1016/j.ejrad.2018.07.028
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。